Last reviewed · How we verify

Misoprostol, per-oral tablets

Tampere University Hospital · FDA-approved active Small molecule

Misoprostol, per-oral tablets is a Prostaglandin analogue Small molecule drug developed by Tampere University Hospital. It is currently FDA-approved for Prevention of NSAID-induced gastric ulcers, Treatment of gastric ulcers, Cervical ripening and labor induction. Also known as: Cytotec.

Misoprostol is a prostaglandin E1 analogue that binds to prostaglandin receptors to increase gastric mucus production and reduce gastric acid secretion.

Misoprostol is a prostaglandin E1 analogue that binds to prostaglandin receptors to increase gastric mucus production and reduce gastric acid secretion. Used for Prevention of NSAID-induced gastric ulcers, Treatment of gastric ulcers, Medical abortion (in combination with mifepristone).

At a glance

Generic nameMisoprostol, per-oral tablets
Also known asCytotec
SponsorTampere University Hospital
Drug classProstaglandin analogue
TargetProstaglandin E1 receptor (EP receptor)
ModalitySmall molecule
Therapeutic areaGastroenterology; Obstetrics
PhaseFDA-approved

Mechanism of action

Misoprostol acts as a synthetic prostaglandin analogue that activates EP3 and other prostaglandin receptors on gastric mucosa. This stimulates mucus and bicarbonate secretion while simultaneously reducing gastric acid production, thereby protecting the gastric lining. It is commonly used to prevent nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers and is also employed for cervical ripening and labor induction due to its uterotonic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Misoprostol, per-oral tablets

What is Misoprostol, per-oral tablets?

Misoprostol, per-oral tablets is a Prostaglandin analogue drug developed by Tampere University Hospital, indicated for Prevention of NSAID-induced gastric ulcers, Treatment of gastric ulcers, Cervical ripening and labor induction.

How does Misoprostol, per-oral tablets work?

Misoprostol is a prostaglandin E1 analogue that binds to prostaglandin receptors to increase gastric mucus production and reduce gastric acid secretion.

What is Misoprostol, per-oral tablets used for?

Misoprostol, per-oral tablets is indicated for Prevention of NSAID-induced gastric ulcers, Treatment of gastric ulcers, Cervical ripening and labor induction.

Who makes Misoprostol, per-oral tablets?

Misoprostol, per-oral tablets is developed and marketed by Tampere University Hospital (see full Tampere University Hospital pipeline at /company/tampere-university-hospital).

Is Misoprostol, per-oral tablets also known as anything else?

Misoprostol, per-oral tablets is also known as Cytotec.

What drug class is Misoprostol, per-oral tablets in?

Misoprostol, per-oral tablets belongs to the Prostaglandin analogue class. See all Prostaglandin analogue drugs at /class/prostaglandin-analogue.

What development phase is Misoprostol, per-oral tablets in?

Misoprostol, per-oral tablets is FDA-approved (marketed).

What are the side effects of Misoprostol, per-oral tablets?

Common side effects of Misoprostol, per-oral tablets include Diarrhea, Abdominal pain, Nausea, Dyspepsia, Uterine contractions (when used for labor induction).

What does Misoprostol, per-oral tablets target?

Misoprostol, per-oral tablets targets Prostaglandin E1 receptor (EP receptor) and is a Prostaglandin analogue.

Related